Cost of outpatient blood transfusion in cancer patients

Journal of Clinical Oncology

Volumn 18, Issue 14, 2000, Pages 2755-2761

  Crémieux, Pierre Yves ^a   Barrett, Barbara ^a   Anderson, Kenneth ^a   Slavin, Mitchell B ^a  

^a Ortho McNeil Pharmaceutical Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANEMIA; ARTICLE; BLOOD TRANSFUSION; CANCER; CANCER PATIENT; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

EID: 17144445726     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.14.2755     Document Type: Article

References (5)

1. Forbes JM, Anderson MD, Anderson GF, et al: Blood transfusion costs: A multicenter study. Transfusion 31:318-323, 1991
2. Mohandas K, Aledort L: Transfusion requirements, risks, and costs for patients with malignancy. Transfusion 35:427-430, 1995
3. Cantor SB, Hudson DV Jr, Lichtiger B, et al: The costs of blood transfusion: A process-flow analysis. J Clin Oncol 16:2364-2370, 1998
4. Sheffield RE, Sullivan SD, Saltiel E, et al: Cost comparison of recombinant human erythropoietin and blood transfusion in cancer chemotherapy induced anemia. Ann Pharmacother 31:15-22, 1997
5. Cremieux PY, Finkelstein SN, Berndt ER, et al: Cost-effectiveness, quality-adjusted life years, and supportive care: Recombinant human erythropoietin as treatment of cancer-associated anemia. Pharmacoeconomics 16:459-472, 1999